

T S1/7

1/7/1

DIALOG(R) File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

013979457

WPI Acc No: 2001-463671/200150

**Oral dosage tablet for sustained release of fluvastatin, comprises hydroxypropyl methyl cellulose polymer and other excipients that are color stable upon prolonged periods of storage**

Patent Assignee: NOVARTIS AG (NOVS ); NOVARTIS-ERFINDUNGEN VERW GES MBH (NOVS )

Inventor: KALB O; VALAZZA S; KALB O M; VALAZZA S J

Number of Countries: 096 Number of Patents: 010

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 6242003	B1	20010605	US 2000549222	A	20000413	200150 B
WO 200178680	A2	20011025	WO 2001EP4204	A	20010411	200166
AU 200162196	A	20011030	AU 200162196	A	20010411	200219
NO 200204891	A	20021205	WO 2001EP4204	A	20010411	200305
			NO 20024891	A	20021010	
CZ 200203379	A3	20030115	WO 2001EP4204	A	20010411	200309
			CZ 20023379	A	20010411	
EP 1272166	A2	20030108	EP 2001936232	A	20010411	200311
			WO 2001EP4204	A	20010411	
SK 200201462	A3	20030401	WO 2001EP4204	A	20010411	200331
			SK 20021462	A	20010411	
BR 200109943	A	20030527	BR 20019943	A	20010411	200344
			WO 2001EP4204	A	20010411	
KR 2003019332	A	20030306	KR 2002712592	A	20020924	200345
CN 1422151	A	20030604	CN 2001807914	A	20010411	200356

Priority Applications (No Type Date): US 2000549222 A 20000413

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

US 6242003 B1 6 A61K-009/22

WO 200178680 A2 E A61K-009/00

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200162196 A A61K-009/00 Based on patent WO 200178680

NO 200204891 A A61K-009/16

CZ 200203379 A3 A61K-009/16 Based on patent WO 200178680

EP 1272166 A2 E A61K-009/20 Based on patent WO 200178680

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

SK 200201462 A3 A61K-009/00 Based on patent WO 200178680

BR 200109943 A A61K-009/00 Based on patent WO 200178680

KR 2003019332 A A61K-031/404

CN 1422151 A A61K-009/20

Abstract (Basic): US 6242003 B1

NOVELTY - A color-stable sustained release tablet containing granules with a mean particle size of less than 200 microns and comprising fluvastatin and a hydroxypropyl methyl cellulose polymer (HPMC) comprising up to 12 % hydroxypropyl functionality, having a

number average molecular weight of 20000-170000 and being present in an amount of 15-50 wt.% based on the total weight of the composition, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for preparing a color stable sustained release oral dosage pharmaceutical composition comprising fluvastatin and a hydroxypropyl methyl cellulose polymer, by storing the composition at a relative humidity of no greater than 75 % and a temperature of 25 degrees Centigrade, the method preventing or reducing the formation of gel in the polymer.

ACTIVITY - Anticholesterol. No biological data is given.

MECHANISM OF ACTION - High mobility group (HMG) CoA reductase inhibitor.

USE - The tablets are used for the sustained release of fluvastatin and for reducing blood cholesterol levels in patients.

ADVANTAGE - The compositions of the invention are color-stable upon prolonged periods of storage and they are designed to overcome the discoloration associated with the formation of hydroxypropyl methyl cellulose polymer gel-like domains which lead to an unsightly, uneven mottled appearance.

pp; 6 DwgNo 0/0

Derwent Class: A96; B07

International Patent Class (Main): A61K-009/00; A61K-009/16; A61K-009/20; A61K-009/22; A61K-031/404

International Patent Class (Additional): A61K-009/14; A61K-009/26; A61K-009/36; A61K-031/405; A61K-047/38; A61P-009/00

?